The report of the National Cancer Institute Translational Research ... evidence of antitumor activity from human clinical trials using a specific antigen; evidence of immune responses in vivo ...

1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut. 2Department of Genetics, Yale University School of Medicine, New Haven, Connecticut.

(2) These cells are activated using anti-CD3/CD28 antibodies to stimulate their proliferation. (3) Genetic modification of the T cells is performed by inserting the CAR gene, enabling them to ...

Although the existence of specific transplantation resistance antigens in transplantable tumors has been known for some time, their exact role in primary tumor induction or repression was not known ...

Emmy-winning 'Today' show weatherman Al Roker will be in Des Moines this weekend to serve as the keynote speaker for the 2025 ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

The loading of tumor antigens endows VLPs with the capability to stimulate tumor antigen-specific immune responses, conferring on the immune system an “aiming ability” allowing the immune system to ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

In situ, the modification was able to direct engineered Tcr-T1 against other HLA-A*2402-positive malignant cancer cell lines with significant antigen-specific cytotoxicity despite their inherent ...